Barinthus Biotherapeutics Plc's

Name: Barinthus Biotherapeutics Plc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

BRNS Sales vs. its Competitors Q2 2026

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Barinthus Biotherapeutics Plc recorded a net loss, as well as most of its competitors.

<< BRNS Stock Performance Comparisons

Barinthus Biotherapeutics Plc's Comment on Competition and Industry Peers

The company faces challenges in patent protection, as patents that are not sufficiently broad may enable competitors to develop similar products. It depends on licenses from third parties for technology and product development, and non-compliance with these agreements could affect business relationships. Its pharmaceutical products compete with lower-priced products in foreign countries with price controls and with imported foreign products. The company is also subject to healthcare regulations and enforcement in the United States and internationally, including laws such as the Anti-Kickback Statute, the False Claims Act, and the Health Insurance Portability and Accountability Act (HIPAA).

<< See the full list of BRNS competitors

*Market share is calculated based on total revenue.

BRNS's Stock Performance relative to its Competitors

Publicly Traded Peers of Barinthus Biotherapeutics Plc

Inovio Pharmaceuticals Inc
Share Performance

-26.04%

This Year

Inovio Pharmaceuticals Inc

Profile

Inovio Pharmaceuticals Inc is a biotechnology company that focuses on the development and commercialization of immunotherapies for the treatment of various diseases, including cancers and infectious diseases. Their business model involves leveraging their proprietary platforms, such as DNA-based technology and electroporation, to design and develop novel vaccines and therapies which are then advanced through clinical trials and potential partnerships for further commercialization.

More about Inovio Pharmaceuticals Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 102.024 mill.	$ - mill.	$ -67.427 mill.

Sources: Barinthus Biotherapeutics Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Friday, September 4, 2026 10:21 AM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Barinthus Biotherapeutics Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.